Treatments Comparison for Skin Vasculitis
(ARAMIS Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing three different drugs to find the best treatment for patients with isolated skin vasculitis. The drugs help by reducing inflammation and controlling the immune system.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but if you are taking prednisone for skin vasculitis, you will need to stop it within 6 weeks after starting the study drug, following a specific tapering schedule. If you are on a low and stable dose of glucocorticoids for other conditions, you can continue that dose during the study.
What data supports the effectiveness of the drug for treating skin vasculitis?
Research shows that Dapsone, a component of the treatment, has been effective in treating severe skin vasculitis and other inflammatory skin conditions, leading to remission in some cases. Additionally, Colchicine has been beneficial in managing prolonged skin symptoms in vasculitis, particularly in cases resistant to other treatments.12345
Is the treatment generally safe for humans?
Dapsone has been used safely in humans for various skin conditions, showing anti-inflammatory effects without increasing side effects when combined with other treatments. Azathioprine, however, may have more side effects compared to alternatives like mycophenolate mofetil, which is considered safer.12678
How does the drug combination of Azathioprine, Colchicine, and Dapsone differ from other treatments for skin vasculitis?
This drug combination is unique because it combines Azathioprine, known for its safety in treating various skin conditions, with Colchicine and Dapsone, which are effective for chronic or relapsing skin vasculitis and urticarial vasculitis. Dapsone, in particular, has shown success in treating severe and chronic vasculitic ulcerations where other immunosuppressants have failed.124910
Eligibility Criteria
Adults with isolated skin vasculitis, confirmed by biopsy, lasting at least 1 month or having multiple flares. Eligible participants have primary skin vasculitis without serious extra-skin symptoms and may have used steroids before joining. Excluded are those with contraindications to the study drugs, systemic vasculitis signs, active cancer in the last 5 years, severe infections or organ insufficiency.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Stage 1
Participants are randomized to receive one of three medications (colchicine, dapsone, or azathioprine) for 6 months
Follow-up
Participants are monitored for response to treatment and side effects
Treatment Stage 2
Participants who discontinue the initial treatment are re-randomized to receive one of the remaining two medications for another 6 months
Treatment Details
Interventions
- Azathioprine (Immunosuppressant)
- Colchicine (Anti-inflammatory agent)
- Dapsone (Anti-inflammatory agent)
Azathioprine is already approved in European Union, United States, Canada for the following indications:
- Prevention of rejection in organ transplantation
- Treatment of autoimmune diseases such as rheumatoid arthritis
- Prevention of rejection in organ transplantation
- Treatment of rheumatoid arthritis
- Prevention of rejection in organ transplantation
- Treatment of rheumatoid arthritis